The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N06 | Psychoanaleptics | |
3
|
N06D | Anti-dementia drugs | |
4
|
N06DA | Anticholinesterases | |
5
|
N06DA03 | Rivastigmine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 9 mg | |
| T-DERMAL | Transdermal | 9.5 mg |
| Active Ingredient |
|---|
|
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer’s disease and Parkinson’s disease. |
| Document | Type | Information Source | |
|---|---|---|---|
| EXELON Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
| EXELON Transdermal patch | MPI, EU: SmPC | European Medicines Agency (EU) | |
| NIMVASTID Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.